Axplora

Axplora is a global leader in active pharmaceutical ingredient (API) manufacturing, offering contract development and manufacturing organisation (CDMO) solutions to pharmaceutical and biotechnology companies.

Formed through the merger of PharmaZell and Novasep, Axplora combines decades of expertise to deliver high-quality, technologically advanced API products and services. With a workforce of over 2,400 employees across nine industrial sites in Europe and India, and a research and development centre in the United States, the company serves more than 900 customers worldwide. Axplora is dedicated to enhancing the development and production of essential medicines, focusing on sustainability and innovation to benefit millions of patients globally.

Key Products and Services:

• API Manufacturing: Production of non-sterile and sterile steroids, specialty APIs, and complex small molecules.
• CDMO Services: Comprehensive support for the development and manufacturing of small molecule and biomolecular APIs, including high-potency APIs (HPAPIs).
• Antibody-Drug Conjugate (ADC) Manufacturing: Expertise in ADC production, with recent investments to expand capabilities in this area.
• Specialised Technologies: Utilisation of advanced techniques such as hazardous chemistry, electrochemistry, flow chemistry, and solid-state chemistry to deliver innovative solutions.

Axplora's commitment to excellence is reflected in its continuous investment in cutting-edge technologies and expansion of production capacities. By fostering strong partnerships with clients, the company strives to accelerate the availability of critical medicines, ensuring they are developed and manufactured efficiently, safely, and sustainably for patients around the world.